Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?
Abstract Carbonic anhydrases (CAs, EC 4.2. 1.1) are widely distributed metalloenzymes in
both prokaryotes and eukaryotes. They efficiently catalyze the reversible hydration of carbon …
both prokaryotes and eukaryotes. They efficiently catalyze the reversible hydration of carbon …
Advances in structure-based drug discovery of carbonic anhydrase inhibitors
CT Supuran - Expert opinion on drug discovery, 2017 - Taylor & Francis
Introduction: The enzyme carbonic anhydrase (CA, EC 4.2. 1.1) is found in numerous
organisms across the tree of life, with seven distinct classes known to date. CA inhibition can …
organisms across the tree of life, with seven distinct classes known to date. CA inhibition can …
Inhibition of carbonic anhydrase IX targets primary tumors, metastases, and cancer stem cells: three for the price of one
CT Supuran, V Alterio, A Di Fiore… - Medicinal research …, 2018 - Wiley Online Library
Human carbonic anhydrase (CA) IX is a tumor‐associated protein, since it is scarcely
present in normal tissues, but highly overexpressed in a large number of solid tumors, where …
present in normal tissues, but highly overexpressed in a large number of solid tumors, where …
A decade of tail-approach based design of selective as well as potent tumor associated carbonic anhydrase inhibitors
Human carbonic anhydrase (hCA) isoforms hCA IX and hCA XII are well established
anticancer drug targets and their selective inhibition is highly desired for the proper …
anticancer drug targets and their selective inhibition is highly desired for the proper …
pH regulators and their inhibitors in tumor microenvironment
S Liao, G Wu, Z **e, X Lei, X Yang, S Huang… - European journal of …, 2024 - Elsevier
As an important characteristic of tumor, acidic tumor microenvironment (TME) is closely
related to immune escape, invasion, migration and drug resistance of tumor. The acidity of …
related to immune escape, invasion, migration and drug resistance of tumor. The acidity of …
Acetazolamide for the treatment of idiopathic intracranial hypertension
CT Supuran - Expert Review of Neurotherapeutics, 2015 - Taylor & Francis
Idiopathic intracranial hypertension (IIH) is characterized by an increase of intracranial
pressure in the absence of neurologic tumors. The sulfonamide carbonic anhydrase (CA, EC …
pressure in the absence of neurologic tumors. The sulfonamide carbonic anhydrase (CA, EC …
Novel carbonic anhydrase inhibitors with dual-tail core sulfonamide show potent and lasting effects for glaucoma therapy
Glaucoma, a leading cause of irreversible vision loss worldwide, is characterized by
elevated intraocular pressure (IOP), a well-established risk factor across all its forms. We …
elevated intraocular pressure (IOP), a well-established risk factor across all its forms. We …
Carbonic anhydrase inhibition and the management of glaucoma: a literature and patent review 2013-2019
Introduction: Glaucoma affects more than 70 million people worldwide. One of the major
therapeutic options for its management is based on the inhibition of the metalloenzyme …
therapeutic options for its management is based on the inhibition of the metalloenzyme …
An update on synthesis of coumarin sulfonamides as enzyme inhibitors and anticancer agents
L Rubab, S Afroz, S Ahmad, S Hussain, I Nawaz… - Molecules, 2022 - mdpi.com
Coumarin is an important six-membered aromatic heterocyclic pharmacophore, widely
distributed in natural products and synthetic molecules. The versatile and unique features of …
distributed in natural products and synthetic molecules. The versatile and unique features of …
Ocular disease therapeutics: design and delivery of drugs for diseases of the eye
The ocular drug discovery field has evidenced significant advancement in the past decade.
The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet …
The FDA approvals of Rhopressa, Vyzulta, and Roclatan for glaucoma, Brolucizumab for wet …